
Photo from Melvin LK Chua/X
Mar 11, 2024, 17:58
Melvin Chua: Interesting results from LEAP010 – combo Pembro with Levatinib or Carbozatinib
Melvin Chua, Head of the Department of Head Neck and Thoracic Cancers, Division of Radiation Oncology at National Cancer Centre Singapore, shared on X/Twitter:
“Interesting results from LEAP010 – combo Pembro with Levatinib or Carbozatinib. Evidently increased ORR, possibly PFS but no difference in OS
Loss of OS signal due to effective salvage regimens?”
Source: Melvin Chua/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 25, 2025, 11:33
Feb 25, 2025, 11:24
Feb 25, 2025, 11:23
Feb 25, 2025, 11:17
Feb 25, 2025, 11:15
Feb 25, 2025, 11:11
Feb 25, 2025, 11:04
Feb 25, 2025, 11:03
Feb 25, 2025, 10:56